ClinicalTrials.gg
CompletedNCT02980341Updated Oct 30, 2024Results posted

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

A Phase 1/2 interventional study of Patritumab Deruxtecan in Metastatic Breast Cancer, sponsored by Daiichi Sankyo Co., Ltd.. Completed at 26 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-30.

Sponsored by Daiichi Sankyo Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing patritumab deruxtecan in Breast Neoplasms — 7 open to participants now, 9 under way, 1 of them phase 3. patritumab deruxtecan · Breast Neoplasms.

Enrollment
5th of 12
182 · median 167
Started
2016
the only one that year
Phase 1/2
4 of 12
3 open now
Registered
1st of 12
by date
Lead sponsor
1 of 12
Daiichi Sankyo Co., Ltd.

Among the 12 studies testing patritumab deruxtecan in Breast Neoplasms, this one is the 5th largest by enrollment, is the only one that started in 2016, is one of 4 in phase 1/2, and was the 1st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 12 studies testing patritumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About patritumab deruxtecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing patritumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, three-part, multiple-dose study to evaluate safety, tolerability, and efficacy of U3-1402 in patients with HER3-positive metastatic breast cancer. HER3 is a unique member of the human epidermal growth factor receptor, which defines a certain type of cancer.

The number of patients and treatment cycles are not fixed in this study. Subjects who continue to derive clinical benefit from the study treatment in the absence of withdrawal of consent, progressive disease (PD), unacceptable toxicity, or death may continue the study treatment until the end of the trial.

03

Conditions studied

  • Metastatic Breast Cancer

Keywords

  • Oncology
  • HER3
  • Antibody drug conjugate
  • Developmental Phase I/II
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Is 18 Years and older in the United States or 20 Years and older in Japan
  2. Has a documented advanced/unresectable or breast cancer
  3. Documented HER3-positive disease measured by immunohistochemistry (IHC)
  4. Has disease that is to or intolerable with standard treatment, or for which standard treatment no longer is available
  5. Has an Performance Status 0-1
  6. Has ≥ 50%
  7. Has based on (RECIST) version 1.1

    Additional Inclusion Criteria for Dose Finding Part and Dose Expansion Part:

  8. Has received 2-6 prior chemotherapy regimens for breast cancer, at least 2 of which were administered for treatment of advanced/unresectable or metastatic disease. At least 1 prior chemotherapeutic regimen must have included a taxane, administered in the , adjuvant, or advanced setting. (With exception of Dose Expansion Part TNBC cohort. See additional inclusion criteria for Dose Expansion Part TNBC cohort.)

    Additional Inclusion Criteria for Dose Expansion Part Only:

  9. Is able to submit a fresh tumor sample prior to starting study treatment if not already submitted for HER3 expression
  10. Has documented hormone (estrogen and/or progesterone) receptor (HR)-positive and negative expression according to American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) guidelines. (With exception of Dose Expansion Part TNBC cohort. See additional inclusion criteria for Dose Expansion Part TNBC cohort.)

    Additional Inclusion Criteria for Dose Expansion Part TNBC cohort Only:

  11. Has documented hormone (estrogen and progesterone) receptor (HR)-negative and HER2 negative expression according to American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) guidelines
  12. Has progressed after receiving 1 to 2 prior chemotherapy regimens for advanced/unresectable or metastatic breast cancer.

Key Exclusion Criteria:

  1. Prior treatment with a HER3 antibody
  2. Prior treatment with an antibody-drug conjugate (ADC) which consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, DS-8201)
  3. Has a medical history of symptomatic congestive heart failure ( classes II-IV) or serious cardiac arrhythmia requiring treatment
  4. Has a medical history of myocardial infarction or unstable angina
  5. Has a prolongation to > 450 millisecond (ms) in males and > 470 ms in females
  6. Has a medical history of lung diseases (eg, interstitial pneumonia, pneumonitis, pulmonary fibrosis, and radiation pneumonitis) or who are suspected to have these diseases by imaging at screening period
  7. Has clinically significant corneal disease

    Additional Exclusion Criteria for Dose Expansion Part:

  8. Prior treatment with an govitecan derivative (eg, IMMU-132).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
182 participants (actual)

Study arms

  • Experimental
    Dose Escalation Part

    Participants receive U3-1402 from 1.6 mg/kg to 8.0 mg/kg, administered via intravenous (IV) solution at 3-week intervals.

    Drug: Patritumab Deruxtecan

  • Experimental
    Dose Finding Part

    Participants receive 1 of 5 different U3-1402 dosing regimens, administered via IV solution at 2 or 3-week intervals at doses at or lower than those studied in the Dose Escalation Part.

    Drug: Patritumab Deruxtecan

  • Experimental
    Dose Expansion Part

    Participants with HER3 high, HER2 negative, HR positive status receive 4.8 mg/kg or 6.4 mg/kg of U3-1402 administered via intravenous (IV) solution at 3-week intervals. Participants with HER3 low, HER2 negative, HR positive status receive 6.4 mg/kg of U3-1402 administered via intravenous (IV) solution at 3-week intervals. Participants with HER3 high, HER2 negative, HR negative status receive 6.4 mg/kg of U3-1402 administration via intravenous (IV) solution at 3-week intervals.

    Drug: Patritumab Deruxtecan

Interventions

  • U3-1402 consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a)

    Also known as: U3-1402

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs)

    AEs will be collected systematically from signing of the informed consent form (ICF) through 28 days after last dose

    Time frame: Baseline up to 28 days post last dose, up to approximately 9 months

  2. Number of Participants With Best Overall Tumor Response Using Blinded Independent Central Review Based on Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1

    CR was defined as a disappearance of all target and non-target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target and non-target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target and non-target lesions. Objective response rate is the number of patients with confirmed complete response and confirmed partial response.

    Time frame: From screening until disease progresses, up to approximately 9 months

Secondary outcomes

  1. Dose Escalation Part: Area Under the Serum Concentration Time Curve (AUC) of Anti-HER3-ac-DXd

    The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.

    Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)

  2. Dose Finding Part: AUC of Anti-HER3-ac-DXd

    The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.

    Time frame: Cycle 1, Day 1 to Cycle 4, Day 21 (each cycle is 21 days)

  3. Dose Expansion Part: AUC of Anti-HER3-ac-DXd

    The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.

    Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)

  4. Dose Escalation Part: Maximum Plasma Concentration (Cmax) of Anti-HER3-ac-DXd

    The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.

    Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)

  5. Dose Finding Part: Cmax of Anti-HER3-ac-DXd

    The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.

    Time frame: Cycle 1, Day 1 to Cycle 4, Day 21 (each cycle is 21 days)

  6. Dose Expansion Part: Cmax of Anti-HER3-ac-DXd

    The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.

    Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)

  7. Dose Escalation Part: Time to Maximum Plasma Concentration (Tmax) of Anti-HER3-ac-DXd

    The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.

    Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)

  8. Dose Finding Part: Tmax of Anti-HER3-ac-DXd

    The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.

    Time frame: Cycle 1, Day 1 to Cycle 4, Day 21 (each cycle is 21 days)

  9. Dose Expansion Part: Tmax of Anti-HER3-ac-DXd

    The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.

    Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)

  10. Dose Escalation Part: Area Under the Concentration-Time Curve of Total Anti-HER3 Antibody

    The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.

    Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)

  11. Dose Finding Part: Area Under the Concentration-Time Curve in Total Anti-HER3 Antibody

    The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.

    Time frame: Cycle 1, Day 1 to Cycle 4, Day 21 (each cycle is 21 days)

  12. Dose Expansion Part: Area Under the Concentration-Time Curve in Total Anti-HER3 Antibody

    The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.

    Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)

  13. Dose Escalation Part: Cmax of Total Anti-HER3 Antibody

    The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.

    Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)

  14. Dose Finding Part: Cmax of Anti-HER3 Antibody

    The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.

    Time frame: Cycle 1, Day 1 to Cycle 4, Day 21 (each cycle is 21 days)

  15. Dose Expansion Part: Cmax in Anti-HER3 Antibody

    The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.

    Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)

  16. Dose Escalation Part: Tmax of Total Anti-HER3 Antibody

    The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.

    Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)

  17. Dose Finding Part: Tmax of Anti-HER3 Antibody

    The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.

    Time frame: Cycle 1, Day 1 to Cycle 4, Day 21 (each cycle is 21 days)

  18. Dose Expansion Part: Tmax in Anti-HER3 Antibody

    The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.

    Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)

07

Results

Posted Aug 13, 2024

Participant flow

A total of 182 participants who met all inclusion criteria and no exclusion criteria received at least 1 dose of study treatment.

Dose Escalation
Participant flow — Dose Escalation
MilestoneDose Escalation: Cohort 1.6 mg/kgDose Escalation: Cohort 3.2 mg/kgDose Escalation/Dose Finding: Cohort 4.8 mg/kgDose Escalation/Dose Finding: Cohort 6.4 mg/kgDose Escalation: Cohort 8.0 mg/kgDose Finding: 3.2/4.8/6.4 mg/kgDose Finding: 4.2/6.4 mg/kgDose Expansion: HER3 High 4.8 mg/kgDose Expansion: HER3-High 6.4 mg/kgDose Expansion: HER3-Low 6.4 mg/kgDose Expansion: TNBC 6.4 mg/kg
Started3315156000000
Completed00000000000
Not completed3315156000000
Withdrew: Progressive disease per recist v1.13311103000000
Withdrew: Clinical progression00210000000
Withdrew: Adverse event00122000000
Withdrew: Withdrawal by subject00100000000
Withdrew: Due to side effect management of chemotherapy00020000000
Withdrew: Due to investigator's decision00001000000
Dose Finding
Participant flow — Dose Finding
MilestoneDose Escalation: Cohort 1.6 mg/kgDose Escalation: Cohort 3.2 mg/kgDose Escalation/Dose Finding: Cohort 4.8 mg/kgDose Escalation/Dose Finding: Cohort 6.4 mg/kgDose Escalation: Cohort 8.0 mg/kgDose Finding: 3.2/4.8/6.4 mg/kgDose Finding: 4.2/6.4 mg/kgDose Expansion: HER3 High 4.8 mg/kgDose Expansion: HER3-High 6.4 mg/kgDose Expansion: HER3-Low 6.4 mg/kgDose Expansion: TNBC 6.4 mg/kg
Started0000012120000
Completed00000000000
Not completed0000012120000
Withdrew: Progressive disease per recist v1.1000008110000
Withdrew: Adverse event00000300000
Withdrew: Withdrawal by subject00000110000
Dose Expansion
Participant flow — Dose Expansion
MilestoneDose Escalation: Cohort 1.6 mg/kgDose Escalation: Cohort 3.2 mg/kgDose Escalation/Dose Finding: Cohort 4.8 mg/kgDose Escalation/Dose Finding: Cohort 6.4 mg/kgDose Escalation: Cohort 8.0 mg/kgDose Finding: 3.2/4.8/6.4 mg/kgDose Finding: 4.2/6.4 mg/kgDose Expansion: HER3 High 4.8 mg/kgDose Expansion: HER3-High 6.4 mg/kgDose Expansion: HER3-Low 6.4 mg/kgDose Expansion: TNBC 6.4 mg/kg
Started000000033312131
Completed00000000000
Not completed000000033312131
Withdrew: Progressive disease per recist v1.1000000023241723
Withdrew: Clinical progression00000004314
Withdrew: Adverse event00000003013
Withdrew: Death00000000210
Withdrew: Withdrawal by subject00000002010
Withdrew: Due to investigator's decision considering patient's liver condition00000001000
Withdrew: Due to investigator's decision due to patient's general condition00000000100
Withdrew: Due to investigator's decision because patient was a candidate for surgery00000000100
Withdrew: Patient withdrew consent following 50 treatment cycles00000000001

Outcome measures

PrimaryNumber of Participants Reporting Treatment-emergent Adverse Events (TEAEs)

AEs will be collected systematically from signing of the informed consent form (ICF) through 28 days after last dose

Time frame:
Baseline up to 28 days post last dose, up to approximately 9 months
Reported as:
Count of participants · Participants
Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs)
ParticipantsDose Escalation: Cohort 1.6 mg/kgDose Escalation: Cohort 3.2 mg/kgDose Escalation/Dose Finding: Cohort 4.8 mg/kgDose Escalation/Dose Finding: Cohort 6.4 mg/kgDose Escalation: Cohort 8.0 mg/kgDose Finding: 3.2/4.8/6.4 mg/kgDose Finding: 4.2/6.4 mg/kgDose Expansion: HER3 High 4.8 mg/kgDose Expansion: HER3-High 6.4 mg/kgDose Expansion: HER3-Low 6.4 mg/kgDose Expansion: TNBC 6.4 mg/kg
Any TEAE3315156121232312131
Any TEAE Grade ≥321111357420241627
Any TEAE associated with death00000001231
Any TEAE associated with study treatment discontinuation00122304213
Any TEAE associated with dose interruption1271238616151020
Any TEAE associated with dose reduction00235204928
PrimaryNumber of Participants With Best Overall Tumor Response Using Blinded Independent Central Review Based on Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1

CR was defined as a disappearance of all target and non-target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target and non-target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target and non-target lesions. Objective response rate is the number of patients with confirmed complete response and confirmed partial response.

Time frame:
From screening until disease progresses, up to approximately 9 months
Reported as:
Count of participants · Participants
Number of Participants With Best Overall Tumor Response Using Blinded Independent Central Review Based on Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1
ParticipantsDose Escalation: Cohort 1.6 mg/kgDose Escalation: Cohort 3.2 mg/kgDose Escalation/Dose Finding: Cohort 4.8 mg/kgDose Escalation/Dose Finding: Cohort 6.4 mg/kgDose Escalation: Cohort 8.0 mg/kgDose Finding: 3.2/4.8/6.4 mg/kgDose Finding: 4.2/6.4 mg/kgDose Expansion: HER3 High 4.8 mg/kgDose Expansion: HER3-High 6.4 mg/kgDose Expansion: HER3-Low 6.4 mg/kgDose Expansion: TNBC 6.4 mg/kg
Complete response (CR)00000000000
Partial response (PR)015735311575
Stable disease (SD)/Non-CR/Non-PD22782561917721
Progressive disease (PD)10301221733
Nonevaluable (NE)00000012242
Objective response rate (ORR)015735311575
SecondaryDose Escalation Part: Area Under the Serum Concentration Time Curve (AUC) of Anti-HER3-ac-DXd

The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.

Time frame:
Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Reported as:
Mean · ng*d/mL
Dose Escalation Part: Area Under the Serum Concentration Time Curve (AUC) of Anti-HER3-ac-DXd
ng*d/mLDose Escalation: Cohort 1.6 mg/kgDose Escalation: Cohort 3.2 mg/kgDose Escalation/Dose Finding: Cohort 4.8 mg/kgDose Escalation/Dose Finding: Cohort 6.4 mg/kgDose Escalation: Cohort 8.0 mg/kg
AUClast, Cycle 12470 ± 4354420 ± 10208690 ± 107013000 ± 331016700 ± 4170
AUClast, Cycle 324005920 ± 107013800 ± 373020500 ± 407027100
AUCtau, Cycle 12470 ± 4384420 ± 10208600 ± 187013600 ± 302016700 ± 4170
AUCtau, Cycle 324205900 ± 205013700 ± 370020300 ± 320021000 ± 5420
AUCinf, Cycle 12490 ± 4404470 ± 10608990 ± 223014600 ± 351018300 ± 4920
SecondaryDose Finding Part: AUC of Anti-HER3-ac-DXd

The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.

Time frame:
Cycle 1, Day 1 to Cycle 4, Day 21 (each cycle is 21 days)
Reported as:
Mean · ng*d/mL
Dose Finding Part: AUC of Anti-HER3-ac-DXd
ng*d/mLDose Finding: 3.2/4.8/6.4 mg/kgDose Finding: 4.2/6.4 mg/kg
AUClast, Cycle 15540 ± 20207160 ± 1900
AUClast, Cycle 318300 ± 27409360 ± 3670
AUClast, Cycle 4—23100 ± 8130
AUCtau, Cycle 16160 ± 11607630 ± 1920
AUCtau, Cycle 316600 ± 376011600 ± 1880
AUCtau, Cycle 4—22300 ± 8010
AUCinf, Cycle 16220 ± 12007800 ± 1990
SecondaryDose Expansion Part: AUC of Anti-HER3-ac-DXd

The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.

Time frame:
Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Reported as:
Mean · ng*d/mL
Dose Expansion Part: AUC of Anti-HER3-ac-DXd
ng*d/mLDose Expansion: HER3 High 4.8 mg/kgDose Expansion: HER3-High 6.4 mg/kgDose Expansion: HER3-Low 6.4 mg/kgDose Expansion: TNBC 6.4 mg/kg
AUClast, Cycle 110500 ± 285011500 ± 393011100 ± 484011400 ± 3820
AUClast, Cycle 314200 ± 654020000 ± 1440019300 ± 683020400 ± 6230
AUCtau, Cycle 110100 ± 248011900 ± 340011700 ± 443011700 ± 3380
AUCtau, Cycle 315600 ± 685022400 ± 1270020300 ± 683019800 ± 5540
SecondaryDose Escalation Part: Maximum Plasma Concentration (Cmax) of Anti-HER3-ac-DXd

The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.

Time frame:
Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Reported as:
Mean · ng/mL
Dose Escalation Part: Maximum Plasma Concentration (Cmax) of Anti-HER3-ac-DXd
ng/mLDose Escalation: Cohort 1.6 mg/kgDose Escalation: Cohort 3.2 mg/kgDose Escalation/Dose Finding: Cohort 4.8 mg/kgDose Escalation/Dose Finding: Cohort 6.4 mg/kgDose Escalation: Cohort 8.0 mg/kg
Cmax, Cycle 11040 ± 2171740 ± 4212950 ± 6613660 ± 10804210 ± 568
Cmax, Cycle 39481820 ± 2843020 ± 5723870 ± 4883720 ± 973
SecondaryDose Finding Part: Cmax of Anti-HER3-ac-DXd

The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.

Time frame:
Cycle 1, Day 1 to Cycle 4, Day 21 (each cycle is 21 days)
Reported as:
Mean · ng/mL
Dose Finding Part: Cmax of Anti-HER3-ac-DXd
ng/mLDose Finding: 3.2/4.8/6.4 mg/kgDose Finding: 4.2/6.4 mg/kg
Cmax, Cycle 11980 ± 3002370 ± 566
Cmax, Cycle 34230 ± 11202830 ± 760
Cmax, Cycle 4—4310 ± 1120
SecondaryDose Expansion Part: Cmax of Anti-HER3-ac-DXd

The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.

Time frame:
Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Reported as:
Mean · ng/mL
Dose Expansion Part: Cmax of Anti-HER3-ac-DXd
ng/mLDose Expansion: HER3 High 4.8 mg/kgDose Expansion: HER3-High 6.4 mg/kgDose Expansion: HER3-Low 6.4 mg/kgDose Expansion: TNBC 6.4 mg/kg
Cmax, Cycle 13010 ± 6313520 ± 6193630 ± 7443610 ± 878
Cmax, Cycle 33020 ± 6064000 ± 6724150 ± 8924090 ± 506
SecondaryDose Escalation Part: Time to Maximum Plasma Concentration (Tmax) of Anti-HER3-ac-DXd

The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.

Time frame:
Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Reported as:
Median · hours
Dose Escalation Part: Time to Maximum Plasma Concentration (Tmax) of Anti-HER3-ac-DXd
hoursDose Escalation: Cohort 1.6 mg/kgDose Escalation: Cohort 3.2 mg/kgDose Escalation/Dose Finding: Cohort 4.8 mg/kgDose Escalation/Dose Finding: Cohort 6.4 mg/kgDose Escalation: Cohort 8.0 mg/kg
Tmax, Cycle 11.85 (1.80 to 1.88)1.68 (1.65 to 2.05)1.83 (1.70 to 7.13)2.05 (1.68 to 22.83)1.98 (1.77 to 6.92)
Tmax, Cycle 32.181.83 (1.83 to 2.10)1.88 (0.73 to 2.08)2.03 (0.77 to 4.13)4.22 (2.02 to 6.92)
SecondaryDose Finding Part: Tmax of Anti-HER3-ac-DXd

The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.

Time frame:
Cycle 1, Day 1 to Cycle 4, Day 21 (each cycle is 21 days)
Reported as:
Median · hours
Dose Finding Part: Tmax of Anti-HER3-ac-DXd
hoursDose Finding: 3.2/4.8/6.4 mg/kgDose Finding: 4.2/6.4 mg/kg
Tmax, Cycle 11.86 (1.60 to 4.23)2.01 (1.73 to 3.95)
Tmax, Cycle 32.00 (0.82 to 4.00)1.93 (0.60 to 3.95)
Tmax, Cycle 4—1.83 (0.73 to 6.95)
SecondaryDose Expansion Part: Tmax of Anti-HER3-ac-DXd

The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.

Time frame:
Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Reported as:
Median · hours
Dose Expansion Part: Tmax of Anti-HER3-ac-DXd
hoursDose Expansion: HER3 High 4.8 mg/kgDose Expansion: HER3-High 6.4 mg/kgDose Expansion: HER3-Low 6.4 mg/kgDose Expansion: TNBC 6.4 mg/kg
Tmax, Cycle 11.90 (1.72 to 7.92)1.97 (1.60 to 3.98)1.98 (1.75 to 7.50)1.95 (1.67 to 6.78)
Tmax, Cycle 31.78 (0.63 to 7.10)0.93 (0.57 to 6.80)2.02 (0.70 to 7.02)2.03 (0.77 to 6.97)
SecondaryDose Escalation Part: Area Under the Concentration-Time Curve of Total Anti-HER3 Antibody

The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.

Time frame:
Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Reported as:
Mean · ug*d/mL
Dose Escalation Part: Area Under the Concentration-Time Curve of Total Anti-HER3 Antibody
ug*d/mLDose Escalation: Cohort 1.6 mg/kgDose Escalation: Cohort 3.2 mg/kgDose Escalation/Dose Finding: Cohort 4.8 mg/kgDose Escalation/Dose Finding: Cohort 6.4 mg/kgDose Escalation: Cohort 8.0 mg/kg
AUClast, Cycle 1114 ± 14.7219 ± 61.0416 ± 128635 ± 171847 ± 248
AUClast, Cycle 3111312 ± 124700 ± 2341080 ± 2801570
AUCtau, Cycle 1114 ± 14.5219 ± 61.0408 ± 115671 ± 169848 ± 248
AUCtau, Cycle 3111311 ± 122682 ± 1941050 ± 2491200 ± 450
AUCinf, Cycle 1115 ± 14.3226 ± 67.3447 ± 153729 ± 186839 ± 203
SecondaryDose Finding Part: Area Under the Concentration-Time Curve in Total Anti-HER3 Antibody

The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.

Time frame:
Cycle 1, Day 1 to Cycle 4, Day 21 (each cycle is 21 days)
Reported as:
Mean · ug*d/mL
Dose Finding Part: Area Under the Concentration-Time Curve in Total Anti-HER3 Antibody
ug*d/mLDose Finding: 3.2/4.8/6.4 mg/kgDose Finding: 4.2/6.4 mg/kg
AUClast, Cycle 1235 ± 92.7302 ± 87.4
AUClast, Cycle 3933 ± 174486 ± 199
AUClast, Cycle 4—1110 ± 280
AUCtau, Cycle 1253 ± 58.0341 ± 103
AUCtau, Cycle 3839 ± 220616 ± 138
AUCtau, Cycle 4—1090 ± 276
AUCinf, Cycle 1260 ± 63.4335 ± 102
SecondaryDose Expansion Part: Area Under the Concentration-Time Curve in Total Anti-HER3 Antibody

The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.

Time frame:
Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Reported as:
Mean · ug*d/mL
Dose Expansion Part: Area Under the Concentration-Time Curve in Total Anti-HER3 Antibody
ug*d/mLDose Expansion: HER3 High 4.8 mg/kgDose Expansion: HER3-High 6.4 mg/kgDose Expansion: HER3-Low 6.4 mg/kgDose Expansion: TNBC 6.4 mg/kg
AUClast, Cycle 1525 ± 174570 ± 248543 ± 225528 ± 166
AUClast, Cycle 3831 ± 3911070 ± 6561070 ± 3811000 ± 266
AUCtau, Cycle 1483 ± 140564 ± 178580 ± 200542 ± 158
AUCtau, Cycle 3874 ± 3651200 ± 5361030 ± 366940 ± 243
SecondaryDose Escalation Part: Cmax of Total Anti-HER3 Antibody

The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.

Time frame:
Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Reported as:
Mean · ug/mL
Dose Escalation Part: Cmax of Total Anti-HER3 Antibody
ug/mLDose Escalation: Cohort 1.6 mg/kgDose Escalation: Cohort 3.2 mg/kgDose Escalation/Dose Finding: Cohort 4.8 mg/kgDose Escalation/Dose Finding: Cohort 6.4 mg/kgDose Escalation: Cohort 8.0 mg/kg
Cmax, Cycle 139.8 ± 9.5561.6 ± 8.4195.8 ± 13.5136 ± 26.8149 ± 35.3
Cmax, Cycle 337.666.8 ± 11.2112 ± 14.1149 ± 24.7165 ± 25.4
SecondaryDose Finding Part: Cmax of Anti-HER3 Antibody

The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.

Time frame:
Cycle 1, Day 1 to Cycle 4, Day 21 (each cycle is 21 days)
Reported as:
Mean · ug/mL
Dose Finding Part: Cmax of Anti-HER3 Antibody
ug/mLDose Finding: 3.2/4.8/6.4 mg/kgDose Finding: 4.2/6.4 mg/kg
Cmax, Cycle 167.9 ± 11.387.2 ± 33.2
Cmax, Cycle 3139 ± 25.094.9 ± 10.6
Cmax, Cycle 4—145 ± 16.6
SecondaryDose Expansion Part: Cmax in Anti-HER3 Antibody

The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.

Time frame:
Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Reported as:
Mean · ug/mL
Dose Expansion Part: Cmax in Anti-HER3 Antibody
ug/mLDose Expansion: HER3 High 4.8 mg/kgDose Expansion: HER3-High 6.4 mg/kgDose Expansion: HER3-Low 6.4 mg/kgDose Expansion: TNBC 6.4 mg/kg
Cmax, Cycle 1107 ± 20.3129 ± 21.2126 ± 28.4127 ± 24.4
Cmax, Cycle 3121 ± 27.7152 ± 25.8140 ± 29.7146 ± 21.7
SecondaryDose Escalation Part: Tmax of Total Anti-HER3 Antibody

The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.

Time frame:
Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Reported as:
Median · hours
Dose Escalation Part: Tmax of Total Anti-HER3 Antibody
hoursDose Escalation: Cohort 1.6 mg/kgDose Escalation: Cohort 3.2 mg/kgDose Escalation/Dose Finding: Cohort 4.8 mg/kgDose Escalation/Dose Finding: Cohort 6.4 mg/kgDose Escalation: Cohort 8.0 mg/kg
Tmax, Cycle 11.85 (1.80 to 2.17)1.68 (1.65 to 1.70)1.95 (1.70 to 6.87)2.00 (1.82 to 7.00)2.14 (1.77 to 6.92)
Tmax, Cycle 32.181.83 (1.83 to 2.10)1.88 (0.67 to 6.88)2.02 (0.75 to 96.42)2.07 (2.02 to 2.13)
SecondaryDose Finding Part: Tmax of Anti-HER3 Antibody

The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.

Time frame:
Cycle 1, Day 1 to Cycle 4, Day 21 (each cycle is 21 days)
Reported as:
Median · hours
Dose Finding Part: Tmax of Anti-HER3 Antibody
hoursDose Finding: 3.2/4.8/6.4 mg/kgDose Finding: 4.2/6.4 mg/kg
Tmax, Cycle 11.85 (1.60 to 4.07)1.80 (1.73 to 6.83)
Tmax, Cycle 33.80 (0.75 to 6.97)1.93 (0.65 to 4.07)
Tmax, Cycle 4—3.80 (0.67 to 4.10)
SecondaryDose Expansion Part: Tmax in Anti-HER3 Antibody

The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.

Time frame:
Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Reported as:
Median · hours
Dose Expansion Part: Tmax in Anti-HER3 Antibody
hoursDose Expansion: HER3 High 4.8 mg/kgDose Expansion: HER3-High 6.4 mg/kgDose Expansion: HER3-Low 6.4 mg/kgDose Expansion: TNBC 6.4 mg/kg
Tmax, Cycle 11.92 (1.75 to 6.80)2.00 (1.60 to 4.13)1.87 (1.75 to 6.80)1.93 (1.67 to 22.02)
Tmax, Cycle 31.95 (0.68 to 6.97)2.10 (0.73 to 7.17)1.98 (0.73 to 6.98)2.00 (0.65 to 6.90)

Adverse events

Collected over Adverse events were collected from baseline up to 28 days post last dose, up to 9 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Escalation: Cohort 1.6 mg/kg2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Dose Escalation: Cohort 3.2 mg/kg2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Dose Escalation/Dose Finding: Cohort 4.8 mg/kg13/15 (86.7%)3/15 (20%)15/15 (100%)
Dose Escalation/Dose Finding: Cohort 6.4 mg/kg11/15 (73.3%)9/15 (60%)15/15 (100%)
Dose Escalation: Cohort 8.0 mg/kg2/6 (33.3%)2/6 (33.3%)6/6 (100%)
Dose Finding: 3.2/4.8/6.4 mg/kg10/12 (83.3%)4/12 (33.3%)12/12 (100%)
Dose Finding: 4.2/6.4 mg/kg10/12 (83.3%)3/12 (25%)12/12 (100%)
Dose Expansion: HER3 High 4.8 mg/kg22/33 (66.7%)10/33 (30.3%)32/33 (97%)
Dose Expansion: HER3-High 6.4 mg/kg24/31 (77.4%)12/31 (38.7%)31/31 (100%)
Dose Expansion: HER3-Low 6.4 mg/kg18/21 (85.7%)7/21 (33.3%)21/21 (100%)
Dose Expansion: TNBC 6.4 mg/kg16/31 (51.6%)8/31 (25.8%)31/31 (100%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventDose Escalation: Cohort 1.6 mg/kgDose Escalation: Cohort 3.2 mg/kgDose Escalation/Dose Finding: Cohort 4.8 mg/kgDose Escalation/Dose Finding: Cohort 6.4 mg/kgDose Escalation: Cohort 8.0 mg/kgDose Finding: 3.2/4.8/6.4 mg/kgDose Finding: 4.2/6.4 mg/kgDose Expansion: HER3 High 4.8 mg/kgDose Expansion: HER3-High 6.4 mg/kgDose Expansion: HER3-Low 6.4 mg/kgDose Expansion: TNBC 6.4 mg/kg
CellulitisInfections and infestations0/31/30/150/150/60/120/120/330/310/210/31
AtelectasisRespiratory, thoracic and mediastinal disorders1/30/30/150/150/60/120/120/330/310/210/31
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/30/151/151/60/120/120/330/310/210/31
MalaiseGeneral disorders0/30/30/150/151/60/120/120/330/310/210/31
Platelet count decreasedInvestigations0/30/31/152/151/61/120/120/333/310/211/31
NauseaGastrointestinal disorders0/30/30/150/150/61/122/121/330/311/212/31
VomitingGastrointestinal disorders0/30/30/150/150/62/122/122/330/311/210/31
Febrile neutropeniaBlood and lymphatic system disorders0/30/30/150/150/60/120/121/330/312/211/31
Urinary tract infectionInfections and infestations0/30/31/150/150/61/120/120/330/310/211/31
CataractEye disorders0/30/30/150/150/61/120/120/330/310/210/31
Most frequent other events
Showing 10 of 193
Most frequent other events
EventDose Escalation: Cohort 1.6 mg/kgDose Escalation: Cohort 3.2 mg/kgDose Escalation/Dose Finding: Cohort 4.8 mg/kgDose Escalation/Dose Finding: Cohort 6.4 mg/kgDose Escalation: Cohort 8.0 mg/kgDose Finding: 3.2/4.8/6.4 mg/kgDose Finding: 4.2/6.4 mg/kgDose Expansion: HER3 High 4.8 mg/kgDose Expansion: HER3-High 6.4 mg/kgDose Expansion: HER3-Low 6.4 mg/kgDose Expansion: TNBC 6.4 mg/kg
NauseaGastrointestinal disorders2/33/311/1514/156/612/1210/1222/3325/3115/2125/31
StomatitisGastrointestinal disorders0/33/36/157/152/62/122/126/335/3110/2112/31
White blood cell count decreasedInvestigations0/30/39/1514/152/66/122/1212/3310/317/2110/31
Platelet count decreasedInvestigations0/30/310/1513/153/64/124/1215/3313/3111/2117/31
Neutrophil count decreasedInvestigations0/30/310/1513/152/68/123/1215/3310/318/2115/31
Decreased appetiteMetabolism and nutrition disorders2/32/39/1511/154/65/124/1218/3315/318/2118/31
VomitingGastrointestinal disorders2/32/38/159/154/64/123/1215/3313/317/2117/31
AlopeciaSkin and subcutaneous tissue disorders0/30/33/155/154/61/120/127/339/316/218/31
Aspartate aminotransferase increasedInvestigations1/30/310/157/153/63/121/1211/3311/316/2110/31
AnaemiaBlood and lymphatic system disorders1/30/38/158/153/64/121/1213/3319/315/2110/31

Baseline characteristics

Demographic and baseline characteristics were assessed in the Full Analysis Set.

Age, Continuous
Age, Continuous(years)Dose Escalation: Cohort 1.6 mg/kgDose Escalation: Cohort 3.2 mg/kgDose Escalation/Dose Finding: Cohort 4.8 mg/kgDose Escalation/Dose Finding: Cohort 6.4 mg/kgDose Escalation: Cohort 8.0 mg/kgDose Finding: 3.2/4.8/6.4 mg/kgDose Finding: 4.2/6.4 mg/kgDose Expansion: HER3 High 4.8 mg/kgDose Expansion: HER3-High 6.4 mg/kgDose Expansion: HER3-Low 6.4 mg/kgDose Expansion: TNBC 6.4 mg/kgTotal
Mean55.3 ± 10.4162.3 ± 22.7452.1 ± 13.3858.7 ± 11.7650.2 ± 8.4551.8 ± 13.7950.7 ± 11.9256.0 ± 11.9556.9 ± 11.0455.4 ± 12.9258.0 ± 13.7355.6 ± 12.5
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation: Cohort 1.6 mg/kgDose Escalation: Cohort 3.2 mg/kgDose Escalation/Dose Finding: Cohort 4.8 mg/kgDose Escalation/Dose Finding: Cohort 6.4 mg/kgDose Escalation: Cohort 8.0 mg/kgDose Finding: 3.2/4.8/6.4 mg/kgDose Finding: 4.2/6.4 mg/kgDose Expansion: HER3 High 4.8 mg/kgDose Expansion: HER3-High 6.4 mg/kgDose Expansion: HER3-Low 6.4 mg/kgDose Expansion: TNBC 6.4 mg/kgTotal
Female3315156121233312131182
Male000000000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dose Escalation: Cohort 1.6 mg/kgDose Escalation: Cohort 3.2 mg/kgDose Escalation/Dose Finding: Cohort 4.8 mg/kgDose Escalation/Dose Finding: Cohort 6.4 mg/kgDose Escalation: Cohort 8.0 mg/kgDose Finding: 3.2/4.8/6.4 mg/kgDose Finding: 4.2/6.4 mg/kgDose Expansion: HER3 High 4.8 mg/kgDose Expansion: HER3-High 6.4 mg/kgDose Expansion: HER3-Low 6.4 mg/kgDose Expansion: TNBC 6.4 mg/kgTotal
White000000011116634
Black of African American000000012014
Asian3315156121219181524142
American Indian or Alaska Native000000010001
Native Hawaiian or Other Pacific Islander000000000000
Other000000010001
08

Study locations

26 sites
  • Southeastern Regional Medical Center
    Newnan, Georgia 30265, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Albert Einstein College of Medicine
    Bronx, New York 10467, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10022, United States
  • Texas Oncology, P.A.
    Dallas, Texas 75231, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Mays Cancer Center
    San Antonio, Texas 78229, United States
  • National Hospital Organization Hokkaido Cancer Center
    Sapporo-Shi, Hokkaido 003-0804, Japan
  • National Cancer Center Hospital East
    Chiba, 277-8577, Japan
  • Fukushima Medical University Hospital
    Fukushima, 960-1295, Japan
  • Local Independent Administrative Corporation Hiroshima City Hospital Organization Hiroshima City Hiroshima Citizens Hospital
    Hiroshima, 730-518, Japan
  • Hakuaikai Social Medical Corporation Sagara Hospital
    Kagoshima, 892-0833, Japan
  • Kanagawa Cancer Center
    Kanagawa, 241-0815, Japan
  • Kumamoto University Hospital
    Kumamoto, 860-8556, Japan
  • Aichi Cancer Center Hospital
    Nagoya, 464-8681, Japan
  • Nagoya City University Hospital
    Nagoya, 467-8602, Japan
  • National Hospital Organization Osaka National Hospital
    Osaka, 540-0006, Japan
  • Osaka International Cancer Institute
    Osaka, 541-8567, Japan
  • Kindai University Hospital
    Osaka, 589-8511, Japan
  • Saitama Medical University International Medical Center
    Saitama, 350-1298, Japan
  • Saitama Cancer Center
    Saitama, 362 0806, Japan
  • National Cancer Center Hospital
    Tokyo, 104-0045, Japan
  • The Cancer Institute Hospital of Japanese Foundation for Cancer Research
    Tokyo, 135-8550, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/ .

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Aug 2021, 56 months.

Results were first posted in Aug 2024, 2 years 11 months after primary completion. A results delay was requested in Jul 2022.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's 56 months is close to that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2016
First posted
Dec 2, 2016
StartActual
Nov 28, 2016
Primary completionActual
Aug 16, 2021
CompletionActual
Sep 7, 2023
Results delay requested
Jul 18, 2022
Results first posted
Aug 13, 2024
Last update
Oct 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02980341
Responsible party
Sponsor
First posted
Dec 2, 2016
Start date
Nov 28, 2016
Primary completion
Aug 16, 2021
Completion
Sep 7, 2023
Results posted
Aug 13, 2024
Last update
Oct 30, 2024

Study contacts

Global Clinical Leader
study director · Daiichi Sankyo

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Patritumab deruxtecan

Start the discussion